| Bioactivity | Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations[1][2]. | ||||||||||||
| Invitro | Dapivirine (4-64 μM, 24, 48, 72, 96 and 120 hours) inhibits proliferation of glioma cells and induces apoptosis (16 μM, 12-48 h)[1].Dapivirine (8 and 16 μM, 12 h) enhances invasion of glioma cells[1].Dapivirine (16 μM, 12 h, 24 h and 48 h) promotes autophagy in U87 cells[1].Dapivirine (TMC120-R147681) apparently blocks infection in the primary cultures at a 10 nM concentration, but secondary cultures revealed that a 100 nM concentration was needed to completely prevent proviral integration[3]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | Dapivirine | ||||||||||||
| CAS | 244767-67-7 | ||||||||||||
| Formula | C20H19N5 | ||||||||||||
| Molar Mass | 329.40 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|